A novel patient-reported outcome for paediatric localized scleroderma: a qualitative assessment of content validity.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
accepted:
31
08
2019
pubmed:
10
9
2019
medline:
15
5
2021
entrez:
10
9
2019
Statut:
ppublish
Résumé
According to current standards, no existing patient-reported outcome (PRO) measures have high-quality validity evidence for use with individuals diagnosed with paediatric localized scleroderma (LS). This severely hinders patient-centred LS-focused research, including much needed clinical trials. To develop a valid health-related quality of life measure for individuals with paediatric LS and to qualitatively evaluate its content validity using a patient-centred approach. Previously collected qualitative data from youth with LS and their caregivers was used to develop items. The resulting item set was administered in a clinical setting to participants aged 8-18 years old. Cognitive interviews were used to evaluate time to survey completion, readability/understanding of the items, appropriateness of the recall period and construct representation. Seventeen children and adolescents with LS participated in the study. Interviews supported readability, understanding of the items and appropriateness of the recall period in individuals > 10 years old. Revisions were made to simplify the instructions and to be more inclusive of different subtypes of LS. Three items were added to improve content representation. Content validity was supported by the patient-centred development process of the outcome measure and via direct feedback from individuals with LS and their families. Although an important first step, the resulting PRO, termed the Localized Scleroderma Quality of Life Instrument, should be further evaluated in a larger sample before being implemented. What's already known about this topic? No current health-related quality of life (HRQoL) measures have been created using direct input from children and adolescents with localized scleroderma (LS). When compared with qualitative reports of HRQoL impact in youth with all LS subtypes, no existing patient-reported outcome (PRO) measures have appropriate content validity for individuals with paediatric LS. What does this study add? This study proposes a novel LS-specific PRO and is the first qualitative assessment of content validity for any PRO measure in this population. Results from cognitive interviews with children and adolescents support the content validity of the newly developed item set and its ability to capture HRQoL impact in a clinical context. What are the clinical implications of this work? Incorporating a content-valid PRO of HRQoL impact into clinical practice would allow for the valid, ongoing capture of patient experience in LS. Although content validity is an important and necessary step in the process of evaluating validity, items within this novel measure will undergo additional psychometric evaluation before implementation in research and clinical settings.
Sections du résumé
BACKGROUND
According to current standards, no existing patient-reported outcome (PRO) measures have high-quality validity evidence for use with individuals diagnosed with paediatric localized scleroderma (LS). This severely hinders patient-centred LS-focused research, including much needed clinical trials.
OBJECTIVES
To develop a valid health-related quality of life measure for individuals with paediatric LS and to qualitatively evaluate its content validity using a patient-centred approach.
METHODS
Previously collected qualitative data from youth with LS and their caregivers was used to develop items. The resulting item set was administered in a clinical setting to participants aged 8-18 years old. Cognitive interviews were used to evaluate time to survey completion, readability/understanding of the items, appropriateness of the recall period and construct representation.
RESULTS
Seventeen children and adolescents with LS participated in the study. Interviews supported readability, understanding of the items and appropriateness of the recall period in individuals > 10 years old. Revisions were made to simplify the instructions and to be more inclusive of different subtypes of LS. Three items were added to improve content representation.
CONCLUSIONS
Content validity was supported by the patient-centred development process of the outcome measure and via direct feedback from individuals with LS and their families. Although an important first step, the resulting PRO, termed the Localized Scleroderma Quality of Life Instrument, should be further evaluated in a larger sample before being implemented. What's already known about this topic? No current health-related quality of life (HRQoL) measures have been created using direct input from children and adolescents with localized scleroderma (LS). When compared with qualitative reports of HRQoL impact in youth with all LS subtypes, no existing patient-reported outcome (PRO) measures have appropriate content validity for individuals with paediatric LS. What does this study add? This study proposes a novel LS-specific PRO and is the first qualitative assessment of content validity for any PRO measure in this population. Results from cognitive interviews with children and adolescents support the content validity of the newly developed item set and its ability to capture HRQoL impact in a clinical context. What are the clinical implications of this work? Incorporating a content-valid PRO of HRQoL impact into clinical practice would allow for the valid, ongoing capture of patient experience in LS. Although content validity is an important and necessary step in the process of evaluating validity, items within this novel measure will undergo additional psychometric evaluation before implementation in research and clinical settings.
Identifiants
pubmed: 31498874
doi: 10.1111/bjd.18512
pmc: PMC7050359
mid: NIHMS1049430
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
625-635Subventions
Organisme : NIAMS NIH HHS
ID : T32 AR052282
Pays : United States
Organisme : Nancy Taylor Foundation for Chronic Diseases
Pays : International
Organisme : NIAMS NIH HHS
ID : K23 AR059722
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 British Association of Dermatologists.
Références
Arthritis Rheum. 2005 Sep;52(9):2873-81
pubmed: 16142730
J Am Acad Dermatol. 2012 Nov;67(5):881-9
pubmed: 22382198
J Am Acad Dermatol. 2014 May;70(5):904-10
pubmed: 24534655
Rheumatology (Oxford). 2009 Jun;48(6):670-2
pubmed: 19336577
J Pediatr. 2000 Nov;137(5):727-30
pubmed: 11060543
Arthritis Care Res (Hoboken). 2017 Jul;69(7):1082-1087
pubmed: 27696700
J Am Acad Dermatol. 2013 Aug;69(2):214-20
pubmed: 23562760
Value Health. 2011 Dec;14(8):967-77
pubmed: 22152165
Qual Life Res. 2018 Oct;27(10):2525-2532
pubmed: 29922914
Qual Life Res. 2003 May;12(3):229-38
pubmed: 12769135
Rheumatology (Oxford). 2006 May;45(5):614-20
pubmed: 16368732
Arch Dermatol. 2010 Sep;146(9):1044-5
pubmed: 20855712
J Am Acad Dermatol. 2014 Sep;71(3):493-8
pubmed: 24880663
Rheumatology (Oxford). 2010 Feb;49(2):373-81
pubmed: 20008472
Rheumatology (Oxford). 2012 Jul;51(7):1331-3
pubmed: 22513151
Psychol Health Med. 2013;18(6):654-63
pubmed: 23398519
Br J Dermatol. 2015;172(5):1329-37
pubmed: 25483169
J Rheumatol. 1997 Jan;24(1):73-80
pubmed: 9002014
J Rheumatol. 2011 Jan;38(1):167-73
pubmed: 21041272
Res Nurs Health. 2000 Aug;23(4):334-40
pubmed: 10940958
Rheum Dis Clin North Am. 2002 Aug;28(3):603-24
pubmed: 12380372
Autoimmun Rev. 2018 Jul;17(7):727-734
pubmed: 29729451
Semin Arthritis Rheum. 2015 Dec;45(3):284-93
pubmed: 26254121
J Rheumatol. 2010 Oct;37(10):2174-9
pubmed: 20843909
Br J Dermatol. 2015 Mar;172(3):722-8
pubmed: 25381928
Med Care. 2007 May;45(5 Suppl 1):S12-21
pubmed: 17443114
Dermatol Ther. 2012 Mar-Apr;25(2):135-47
pubmed: 22741933
Br J Dermatol. 2020 Jan 18;:
pubmed: 31955419
Health Qual Life Outcomes. 2009 Jan 23;7:3
pubmed: 19166601
Br J Dermatol. 2019 May;180(5):1183-1189
pubmed: 30315656
Arch Dermatol. 2009 Sep;145(9):1017-22
pubmed: 19770441
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Arch Dermatol. 2008 Oct;144(10):1394-5
pubmed: 18936410
Arthritis Rheumatol. 2014 Dec;66(12):3496-504
pubmed: 25156342
Qual Life Res. 2013 Oct;22(8):1889-905
pubmed: 23288613
Br J Dermatol. 2018 Aug;179(2):353-361
pubmed: 29451694